The potential clinical significance of exploiting this interaction between ERα and PR signalling in breast cancer affords the possibility that the addition of a progesterone agonist might enhance the anti-proliferative effect of anti-oestrogen therapies and therefore provide a more effective combination therapy. The gene discussed is ESR1; the disease is breast cancer.